Literature DB >> 30171848

G protein-coupled receptor kinase 2 contributes to impaired fatty acid metabolism in the failing heart.

Jessica Pfleger1, Polina Gross2, Jaslyn Johnson2, Rhonda L Carter1, Erhe Gao1, Douglas G Tilley1, Steven R Houser2, Walter J Koch3.   

Abstract

Increased G protein-coupled receptor kinase (GRK)2 is central to heart failure (HF) pathogenesis, via desensitization of β-adrenergic receptors and loss of contractile reserve. Since GRK2 has been shown to compromise fatty acid (FA) oxidation, this kinase may link metabolic and contractile defects in HF. The aim of this study was to investigate the mechanistic role of GRK2 in FA metabolism and bioenergetics in the heart. For that purpose, we measured FA uptake and cluster of differentiation (CD)36 expression, phosphorylation, and ubiquitination in mice with cardiac-specific overexpression of GRK2 (TgGRK2) or expression of its c-terminus (GRK2 inhibitor- TgβARKct) or in global heterozygous GRK2 knockout (GRK2+/-) mice. Cellular bioenergetics were also measured in isolated cardiomyocytes following adenoviral delivery of exogenous GRK2, βARKct, or short hairpin GRK2 (shGRK2). Additionally, CD36 expression and phosphorylation were evaluated following transverse aortic constriction (TAC) in wild type (WT) and GRK2+/- mice. Our results show a 33% ± 0.81 reduction in FA uptake rate, accompanied by 51% ± 0.17 lower CD36 protein, and 70% ± 0.23 and 69% ± 0.18 increases in CD36 phosphorylation and ubiquitination, respectively, in the TgGRK2 mice. Moreover, an in vitro kinase assay suggests that GRK2 directly phosphorylates CD36. In isolated cardiomyocytes, GRK2 overexpression induced a 26% ± 2.21 decrease in maximal respiration, which was enhanced (20% ± 4.02-5.14) with inhibition of the kinase. Importantly, in hearts with systolic dysfunction, notable reductions in CD36 mRNA and protein, as well as a significant increase in CD36 phosphorylation were normalized in the GRK2+/- mice post-TAC. Thus, we propose that GRK2 up-regulation in HF is, at least partly, responsible for reduced FA uptake and oxidation and may be a nodal link between metabolic and contractile defects.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac fatty acid metabolism; Cluster of differentiation 36; G protein-coupled receptor kinase; Heart failure; Phosphorylation; β-adrenergic signaling

Mesh:

Substances:

Year:  2018        PMID: 30171848     DOI: 10.1016/j.yjmcc.2018.08.025

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  β-Adrenergic receptor, an essential target in cardiovascular diseases.

Authors:  Daniel Chikere Ali; Muhammad Naveed; Andrew Gordon; Fatima Majeed; Muhammad Saeed; Michael I Ogbuke; Muhammad Atif; Hafiz Muhammad Zubair; Li Changxing
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  Measurements of Mitochondrial Respiration in Intact Cells, Permeabilized Cells, and Isolated Tissue Mitochondria Using the Seahorse XF Analyzer.

Authors:  Jessica Pfleger
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Metabolic Determinants in Cardiomyocyte Function and Heart Regenerative Strategies.

Authors:  Magda Correia; Francisco Santos; Rita da Silva Ferreira; Rita Ferreira; Bruno Bernardes de Jesus; Sandrina Nóbrega-Pereira
Journal:  Metabolites       Date:  2022-05-31

4.  A peptide of the amino-terminus of GRK2 induces hypertrophy and yet elicits cardioprotection after pressure overload.

Authors:  Kamila M Bledzka; Iyad H Manaserh; Jessica Grondolsky; Jessica Pfleger; Rajika Roy; Erhe Gao; J Kurt Chuprun; Walter J Koch; Sarah M Schumacher
Journal:  J Mol Cell Cardiol       Date:  2021-02-04       Impact factor: 5.000

5.  HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction.

Authors:  Markus Wallner; Deborah M Eaton; Remus M Berretta; Laura Liesinger; Matthias Schittmayer; Juergen Gindlhuber; Jichuan Wu; Mark Y Jeong; Ying H Lin; Giulia Borghetti; Sandy T Baker; Huaqing Zhao; Jessica Pfleger; Sandra Blass; Peter P Rainer; Dirk von Lewinski; Heiko Bugger; Sadia Mohsin; Wolfgang F Graier; Andreas Zirlik; Timothy A McKinsey; Ruth Birner-Gruenberger; Marla R Wolfson; Steven R Houser
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 19.319

6.  Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure.

Authors:  Michele Ciccarelli; Daniela Sorriento; Antonella Fiordelisi; Jessica Gambardella; Antonietta Franco; Carmine Del Giudice; Marina Sala; Maria Gaia Monti; Alessia Bertamino; Pietro Campiglia; Marco Oliveti; Paolo Poggio; Giovanna Trinchese; Gina Cavaliere; Ersilia Cipolletta; Maria Pina Mollica; Domenico Bonaduce; Bruno Trimarco; Guido Iaccarino
Journal:  ESC Heart Fail       Date:  2020-04-30

Review 7.  G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases.

Authors:  Cristina Murga; Alba C Arcones; Marta Cruces-Sande; Ana M Briones; Mercedes Salaices; Federico Mayor
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

Review 8.  The Metabolic Role of GRK2 in Insulin Resistance and Associated Conditions.

Authors:  Daniela Sorriento; Maria Rosaria Rusciano; Valeria Visco; Antonella Fiordelisi; Federica Andrea Cerasuolo; Paolo Poggio; Michele Ciccarelli; Guido Iaccarino
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

9.  Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses.

Authors:  Ruxu Zhai; Erika L Varner; Ajay Rao; Sunil Karhadkar; Antonio Di Carlo; Nathaniel W Snyder; Priscila Y Sato
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

10.  A Cardiac Amino-Terminal GRK2 Peptide Inhibits Maladaptive Adipocyte Hypertrophy and Insulin Resistance During Diet-Induced Obesity.

Authors:  Iyad H Manaserh; Kamila M Bledzka; Alex Junker; Jessica Grondolsky; Sarah M Schumacher
Journal:  JACC Basic Transl Sci       Date:  2022-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.